207 related articles for article (PubMed ID: 33643691)
21. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
22. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials.
Edwards J; Tasker A; Pires da Silva I; Quek C; Batten M; Ferguson A; Allen R; Allanson B; Saw RPM; Thompson JF; Menzies AM; Palendira U; Wilmott JS; Long GV; Scolyer RA
Clin Cancer Res; 2019 Jun; 25(11):3247-3258. PubMed ID: 30777877
[TBL] [Abstract][Full Text] [Related]
24. Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor.
Kotlan B; Horvath S; Eles K; Plotar VK; Naszados G; Czirbesz K; Blank M; Farkas E; Toth L; Tovari J; Szekacs A; Shoenfeld Y; Godeny M; Kasler M; Liszkay G
Front Immunol; 2019; 10():650. PubMed ID: 31024530
[TBL] [Abstract][Full Text] [Related]
25. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
26. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.
de Azevedo RA; Shoshan E; Whang S; Markel G; Jaiswal AR; Liu A; Curran MA; Travassos LR; Bar-Eli M
Oncoimmunology; 2020 Dec; 9(1):1846915. PubMed ID: 33344042
[TBL] [Abstract][Full Text] [Related]
27. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
28. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
29. Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.
Tang H; Qiu X; Timmerman C; Fu YX
Methods Mol Biol; 2018; 1845():275-286. PubMed ID: 30141019
[TBL] [Abstract][Full Text] [Related]
30. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
Calderaro J; Petitprez F; Becht E; Laurent A; Hirsch TZ; Rousseau B; Luciani A; Amaddeo G; Derman J; Charpy C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C
J Hepatol; 2019 Jan; 70(1):58-65. PubMed ID: 30213589
[TBL] [Abstract][Full Text] [Related]
31. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
32. Poor clinical outcome in metastatic melanoma is associated with a microRNA-modulated immunosuppressive tumor microenvironment.
Jorge NAN; Cruz JGV; Pretti MAM; Bonamino MH; Possik PA; Boroni M
J Transl Med; 2020 Feb; 18(1):56. PubMed ID: 32024530
[TBL] [Abstract][Full Text] [Related]
33. [Intratumoral B cells and tertiary lymphoid structures are biomarkers of survival and immunotherapy responses].
Fridman WH; Petitprez F; Sautes-Fridman C
Bull Cancer; 2020 Apr; 107(4):403-404. PubMed ID: 32284150
[No Abstract] [Full Text] [Related]
34. Regulatory B cells in anti-tumor immunity.
Zhang Y; Gallastegui N; Rosenblatt JD
Int Immunol; 2015 Oct; 27(10):521-30. PubMed ID: 25999597
[TBL] [Abstract][Full Text] [Related]
35. A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapy.
Varn FS; Wang Y; Cheng C
Oncoimmunology; 2019; 8(1):e1513440. PubMed ID: 30546953
[TBL] [Abstract][Full Text] [Related]
36. Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses.
Vats K; Kruglov O; Sahoo B; Soman V; Zhang J; Shurin GV; Chandran UR; Skums P; Shurin MR; Zelikovsky A; Storkus WJ; Bunimovich YL
Cancer Immunol Res; 2022 Sep; 10(9):1141-1154. PubMed ID: 35834791
[TBL] [Abstract][Full Text] [Related]
37. Identification of Tertiary Lymphoid Structure-Associated Follicular Helper T Cells in Human Tumors and Tissues.
Couillault C; Germain C; Dubois B; Kaplon H
Methods Mol Biol; 2018; 1845():205-222. PubMed ID: 30141015
[TBL] [Abstract][Full Text] [Related]
38. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Huang AC; Orlowski RJ; Xu X; Mick R; George SM; Yan PK; Manne S; Kraya AA; Wubbenhorst B; Dorfman L; D'Andrea K; Wenz BM; Liu S; Chilukuri L; Kozlov A; Carberry M; Giles L; Kier MW; Quagliarello F; McGettigan S; Kreider K; Annamalai L; Zhao Q; Mogg R; Xu W; Blumenschein WM; Yearley JH; Linette GP; Amaravadi RK; Schuchter LM; Herati RS; Bengsch B; Nathanson KL; Farwell MD; Karakousis GC; Wherry EJ; Mitchell TC
Nat Med; 2019 Mar; 25(3):454-461. PubMed ID: 30804515
[TBL] [Abstract][Full Text] [Related]
39. Data mining of immune-related prognostic genes in metastatic melanoma microenvironment.
Han W; Huang B; Zhao XY; Shen GL
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33169786
[TBL] [Abstract][Full Text] [Related]
40. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment.
Li N; Kang Y; Wang L; Huff S; Tang R; Hui H; Agrawal K; Gonzalez GM; Wang Y; Patel SP; Rana TM
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20159-20170. PubMed ID: 32747553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
